Stockscreener 앱 받기
0.4768
1.69%
-0.0082
시간 외 거래:
.47
-0.0068
-1.43%
전일 마감가:
$0.485
열려 있는:
$0.4813
하루 거래량:
3.90M
Relative Volume:
6.63
시가총액:
$18.54M
수익:
$356.60K
순이익/손실:
$-24.32M
주가수익비율:
-0.0516
EPS:
-9.24
순현금흐름:
$-27.24M
1주 성능:
-46.83%
1개월 성능:
-54.15%
6개월 성능:
-80.77%
1년 성능:
-85.60%
1일 변동 폭
$0.433
$0.5176
1주일 범위
$0.43
$0.98
52주 변동 폭
$0.43
$11.18
Geovax Labs Inc Stock (GOVX) Company Profile
명칭
Geovax Labs Inc
전화
678-384-7220
주소
1900 LAKE PARK DRIVE, SMYRNA
GOVX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GOVX
Geovax Labs Inc
|
0.4768 | 18.54M | 356.60K | -24.32M | -27.24M | -9.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Geovax Labs Inc Stock (GOVX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-15 | 재확인 | Alliance Global Partners | Buy |
| 2025-04-15 | 재확인 | D. Boral Capital | Buy |
| 2024-11-11 | 개시 | Alliance Global Partners | Buy |
| 2024-07-16 | 개시 | ROTH MKM | Buy |
| 2020-11-19 | 개시 | Maxim Group | Buy |
Geovax Labs Inc 주식(GOVX)의 최신 뉴스
Financial Health Check: Examining Geovax Labs Inc (GOVX)’s Key Ratios - DWinneX
Geovax Labs Inc Inc. (GOVX) Price Performance: Is It Undervalued or Overvalued? - investchronicle.com
GeoVax Labs (GOVX) Gains Positive EMA Feedback, Potential Speedier Approval | GOVX Stock News - GuruFocus
GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting - Yahoo Finance
GeoVax Advances Toward European Approval for Mpox and Smallpox Vaccine with EMA's Support - citybuzz -
GeoVax Labs’ (GOVX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
GeoVax Labs (GOVX) Issues New Stock Units with Warrants | GOVX Stock News - GuruFocus
GeoVax Labs (GOVX) Gains EMA Approval for Phase 3 Vaccine Trial | GOVX Stock News - GuruFocus
GOVX: Geovax Labs Receives Buy Rating from Analyst | GOVX Stock News - GuruFocus
GeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVA - Yahoo Finance
GeoVax to Showcase Innovative Vaccines and Therapies at BIO International Convention 2025 - citybuzz -
GeoVax to Participate in BIO International Convention 2025 - Yahoo Finance
Geovax highlights progress on mpox vaccine and COVID-19 trial advancements - MSN
GeoVax Advances GEO-MVA Vaccine Development Amid WHO's Mpox Emergency Declaration - citybuzz -
GeoVax Responds to WHO's Fourth Declaration of Mpox as a Global Public Health Emergency - Yahoo Finance
Robinhood Markets, Inc. Reports May 2025 Operating Data - The Globe and Mail
GeoVax to Showcase Positive Immune Response Data for GEO-CM04S1 in CLL Patients at EHA 2025 Congress - citybuzz -
GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients - Yahoo Finance
42,275 Shares in GeoVax Labs, Inc. (NASDAQ:GOVX) Acquired by Citadel Advisors LLC - Defense World
GeoVax’s Multi-Antigen COVID-19 Vaccine Candidates Show Promise Against Variants - citybuzz -
GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia - Yahoo Finance
Northern Trust Corp Invests $29,000 in GeoVax Labs, Inc. (NASDAQ:GOVX) - Defense World
GeoVax to Showcase Innovative COVID 19 Vaccine Data at the Keystone Symposia on Vaccinology - Yahoo Finance
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Analysts - Defense World
GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing - Yahoo Finance
GeoVax Labs (NASDAQ:GOVX) Shares Up 6.9% – Should You Buy? - Defense World
GeoVax Commends FDA's Shift to Risk-Based COVID-19 Vaccination Guidance - Yahoo Finance
GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation - Yahoo Finance
GeoVax Reaffirms Urgent Need for Multi-Antigen COVID-19 Vaccines as CDC Shifts Recommendations - Yahoo Finance
GeoVax Labs (GOVX) Projected to Post Earnings on Tuesday - Defense World
GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025 - Yahoo Finance
GeoVax Strengthens Patent Portfolio for Innovative Cancer Therapy Approach - citybuzz -
GeoVax Expands Gedeptin(R) Patent Portfolio - Yahoo Finance
GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production - Yahoo Finance
MarketsMedicine Hat News - FinancialContent
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia - ADVFN
D. Boral Capital Cuts GeoVax Labs (NASDAQ:GOVX) Price Target to $9.00 - Defense World
GeoVax Labs, Inc. (NASDAQ:GOVX) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Form 8-KCurrent report - ADVFN
Geode Capital Management LLC Has $223,000 Holdings in GeoVax Labs, Inc. (NASDAQ:GOVX) - Defense World
Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX) and Baxter International (BAX) - The Globe and Mail
GeoVax Labs Earnings Call: Mixed Sentiment and Future Prospects - TipRanks
Geovax Labs (GOVX) Faces Price Target Reduction by Analyst | GOV - GuruFocus
Geovax Labs (GOVX) Faces Price Target Reduction by Analyst | GOVX Stock News - GuruFocus
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
GeoVax Labs Reports Q1 2025 Progress Amid Challenges - TipRanks
Earnings call transcript: GeoVax Q1 2025 reveals revenue from BARDA contract - Investing.com Australia
GeoVax Labs Q1 2025 Earnings Call Transcript - MarketBeat
GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting - Yahoo Finance
Geovax Labs is a buy, Roth says - Cantech Letter
Geovax Labs Inc (GOVX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Geovax Labs Inc 주식 (GOVX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sharkey John W. | VP, Business Development |
Apr 10 '25 |
Buy |
0.99 |
6,000 |
5,940 |
6,191 |
| DODD DAVID A | President, CEO |
Apr 01 '25 |
Buy |
1.08 |
10,000 |
10,800 |
36,661 |
| Reynolds Mark | CFO |
Mar 31 '25 |
Buy |
1.08 |
6,800 |
7,343 |
14,013 |
| DODD DAVID A | President, CEO |
Aug 09 '24 |
Buy |
1.95 |
8,000 |
15,600 |
26,661 |
1.45%
0.86%
자본화:
|
볼륨(24시간):